, /PRNewswire/ -- , a leader in developing covalent small molecule drugs for traditional "hard-to-drug" targets, announced today that the first patient has been dosed in its Phase 1 clinical trial of BGC515, a novel TEAD inhibitor discovered through BridGene's cutting-edge chemoproteomic platform, IMTACTM. This milestone highlights the potential of BridGene's innovative chemoproteomics approach. The Phase 1 study will enroll subjects in both the US and ( ) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGC515 as a single agent in patients with advanced solid tumors, including malignant mesothelioma, epithelioid hemangioendothelioma, and other solid tumors with hippo pathway dysregulation.
Dr. , Ph.D.
, FRCP, Professor in the Department of Investigational Cancer Therapeutics (Phase I Program) and Head of Clinical Development, Therapeutics Discovery Division at the MD Anderson Cancer Center, is the principal investigator at the initial US site, where the first patient has been enrolled. "We are delighted to begin the clinical evaluation of BGC515 with the dosing of our first patient, and we look forward to the evaluation of the initial safety and efficacy of this exciting compound," said , M.D.
, Chief Medical Officer of BridGene Biosciences. "The initiation and dosing of our first drug in clinical development from our chemoproteomic platform marks a major inflection point for BridGene," stated , Ph.D.
, Co-Founder a.